On this episode, Rich and Pip discuss the very long half life factor VIII product efanesoctocog alfa (trade names Altuvoct and Altuviiio). They discuss the 2023 NEJM paper that has recently prompted its approval for use in the UK NHS. This is the first of two episodes on this subject.

HaemSTAR is an independent UK-wide network of registrars in clinical haematology, interested in promoting and performing research in classical haematology. Our focus is on collaborative projects across haemostasis & thrombosis, transfusion, general haematology, and obstetric haematology.

Hosted on Acast. See acast.com/privacy for more information.